Physician profile

Warner Huh

Gynecologic Oncology · Birmingham, AL

NPI 1043257173

$58,528.72

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$1,830.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Chugai Pharmaceutical Co., Ltd. $20,606.35 2019
Astrazeneca Pharmaceuticals Lp $16,782.50 2021-2022
Roche Diagnostics Corporation $8,173.00 2022
Seagen INC. $8,073.30 2021-2022
Dysis Medical, INC. $2,537.50 2020
Merck Sharp & Dohme LLC $1,830.00 2023 Gardasil 9
Intuitive Surgical, INC. $475.00 2019
Eisai INC. $21.76 2022
Secura Bio, INC. $13.90 2022
Glaxosmithkline, LLC. $13.88 2020
Clovis Oncology, INC. $1.53 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Warner Huh

$58,528.72

in general payments reported 2019-2025

Years
2019-2023
Top company
Chugai Pharmaceutical Co., Ltd.

https://glasscript.com/doctor/137431/warner-huh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.